149 related articles for article (PubMed ID: 27269419)
1. Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis.
Cascella R; Strafella C; Longo G; Maccarone M; Borgiani P; Sangiuolo F; Novelli G; Giardina E
Pharmacogenomics; 2016 Jun; 17(8):943-51. PubMed ID: 27269419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of treatment response in psoriatic arthritis.
Jani M; Barton A; Ho P
Curr Rheumatol Rep; 2015 Jul; 17(7):44. PubMed ID: 25980667
[TBL] [Abstract][Full Text] [Related]
3. Psoriatic arthritis: genetic susceptibility and pharmacogenetics.
Rahman P; O'Rielly DD
Pharmacogenomics; 2008 Feb; 9(2):195-205. PubMed ID: 18370848
[TBL] [Abstract][Full Text] [Related]
4. [Psoriatic arthritis: what the dermatologist needs to know, Part 2].
López-Ferrer A; Torrente-Segarra V; Puig L
Actas Dermosifiliogr; 2010 Nov; 101(9):742-8. PubMed ID: 21034704
[TBL] [Abstract][Full Text] [Related]
5. Psoriatic arthritis: a review.
Amherd-Hoekstra A; Näher H; Lorenz HM; Enk AH
J Dtsch Dermatol Ges; 2010 May; 8(5):332-9. PubMed ID: 20015187
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis.
Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Puppo F
Expert Opin Drug Saf; 2017 Oct; 16(10):1173-1179. PubMed ID: 28750567
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic considerations in the treatment of psoriatic arthritis.
Kavanaugh A
Rheumatology (Oxford); 2006 Jul; 45(7):790-1. PubMed ID: 16705044
[No Abstract] [Full Text] [Related]
8. Diagnosis and management of psoriatic arthritis.
Balakrishnan C; Madnani N
Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S18-24. PubMed ID: 23974691
[TBL] [Abstract][Full Text] [Related]
9. Psoriatic arthritis for the dermatologist.
Tintle SJ; Gottlieb AB
Dermatol Clin; 2015 Jan; 33(1):127-48. PubMed ID: 25412788
[TBL] [Abstract][Full Text] [Related]
10. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
11. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
12. Current concepts and new developments in the treatment of psoriatic arthritis.
Pipitone N; Kingsley GH; Manzo A; Scott DL; Pitzalis C
Rheumatology (Oxford); 2003 Oct; 42(10):1138-48. PubMed ID: 12810935
[TBL] [Abstract][Full Text] [Related]
13. Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.
Lubrano E; Perrotta FM
Drugs; 2016 Apr; 76(6):663-73. PubMed ID: 26957495
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects.
Sutherland A; Power RJ; Rahman P; O'Rielly DD
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):923-35. PubMed ID: 27266955
[TBL] [Abstract][Full Text] [Related]
15. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
[TBL] [Abstract][Full Text] [Related]
16. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
[TBL] [Abstract][Full Text] [Related]
17. A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.
Collins ES; Butt AQ; Gibson DS; Dunn MJ; Fearon U; van Kuijk AW; Gerlag DM; Pontifex E; Veale DJ; Tak PP; FitzGerald O; Pennington SR
Proteomics Clin Appl; 2016 Jun; 10(6):645-62. PubMed ID: 26108918
[TBL] [Abstract][Full Text] [Related]
18. Apremilast for the treatment of psoriatic arthritis.
Varada S; Tintle SJ; Gottlieb AB
Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for psoriatic arthritis.
Olivieri I; D'Angelo S; Palazzi C; Lubrano E; Leccese P
Expert Opin Emerg Drugs; 2010 Sep; 15(3):399-414. PubMed ID: 20528612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
